WO2004094471A3 - Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia - Google Patents

Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia Download PDF

Info

Publication number
WO2004094471A3
WO2004094471A3 PCT/US2004/012445 US2004012445W WO2004094471A3 WO 2004094471 A3 WO2004094471 A3 WO 2004094471A3 US 2004012445 W US2004012445 W US 2004012445W WO 2004094471 A3 WO2004094471 A3 WO 2004094471A3
Authority
WO
WIPO (PCT)
Prior art keywords
hypercholesterolemia
treatment
mediators
cholesterol transport
reverse cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/012445
Other languages
French (fr)
Other versions
WO2004094471A2 (en
Inventor
Jagadish C Sircar
Kashinatham Alisala
Igor Nikoulin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avanir Pharmaceuticals Inc
Original Assignee
Avanir Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0409609-6A priority Critical patent/BRPI0409609A/en
Priority to JP2006513224A priority patent/JP2007534612A/en
Priority to MXJL05000046A priority patent/MXJL05000046A/en
Priority to AU2004233333A priority patent/AU2004233333A1/en
Priority to EP04760126A priority patent/EP1615954A2/en
Priority to CA002522758A priority patent/CA2522758A1/en
Application filed by Avanir Pharmaceuticals Inc filed Critical Avanir Pharmaceuticals Inc
Publication of WO2004094471A2 publication Critical patent/WO2004094471A2/en
Publication of WO2004094471A3 publication Critical patent/WO2004094471A3/en
Priority to IS8072A priority patent/IS8072A/en
Anticipated expiration legal-status Critical
Priority to NO20055474A priority patent/NO20055474L/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides compositions adapted to enhance reverse cholesterol transport in mammals. The compositions are suitable for oral delivery and useful in the treatment and/or prevention of hypercholesterolemia, atherosclerosis and associated cardiovascular diseases.
PCT/US2004/012445 2003-04-22 2004-04-22 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia Ceased WO2004094471A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2006513224A JP2007534612A (en) 2003-04-22 2004-04-22 Reverse cholesterol transport mediator for the treatment of hypercholesterolemia
MXJL05000046A MXJL05000046A (en) 2003-04-22 2004-04-22 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia.
AU2004233333A AU2004233333A1 (en) 2003-04-22 2004-04-22 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
EP04760126A EP1615954A2 (en) 2003-04-22 2004-04-22 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
CA002522758A CA2522758A1 (en) 2003-04-22 2004-04-22 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
BRPI0409609-6A BRPI0409609A (en) 2003-04-22 2004-04-22 reverse cholesterol transport mediators for the treatment of hypercholesterolemia
IS8072A IS8072A (en) 2003-04-22 2005-10-13 Cholesterol transfer agents in the treatment of hypercholesterolemia
NO20055474A NO20055474L (en) 2003-04-22 2005-11-18 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46466703P 2003-04-22 2003-04-22
US60/464,667 2003-04-22

Publications (2)

Publication Number Publication Date
WO2004094471A2 WO2004094471A2 (en) 2004-11-04
WO2004094471A3 true WO2004094471A3 (en) 2005-06-16

Family

ID=33310929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/012445 Ceased WO2004094471A2 (en) 2003-04-22 2004-04-22 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia

Country Status (18)

Country Link
US (1) US20060166891A1 (en)
EP (1) EP1615954A2 (en)
JP (1) JP2007534612A (en)
KR (1) KR20050114283A (en)
CN (1) CN1809590A (en)
AR (1) AR044058A1 (en)
AU (1) AU2004233333A1 (en)
BR (1) BRPI0409609A (en)
CA (1) CA2522758A1 (en)
CL (1) CL2004000858A1 (en)
IS (1) IS8072A (en)
MX (1) MXJL05000046A (en)
NO (1) NO20055474L (en)
PE (1) PE20050136A1 (en)
RU (1) RU2005135139A (en)
TW (1) TW200503747A (en)
UY (1) UY28282A1 (en)
WO (1) WO2004094471A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1753782A1 (en) * 2004-06-09 2007-02-21 Avanir Pharmaceuticals Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
KR20070043711A (en) * 2004-06-09 2007-04-25 아바니르 파마슈티컬스 Small molecule for the treatment of hypercholesterolemia and related diseases
MXJL06000069A (en) * 2004-06-09 2007-04-10 Avanir Pharmaceuticals Heterocyclic derivatives for treatment of hyperlipidemia and related diseases.
WO2006049597A1 (en) * 2004-10-27 2006-05-11 Avanir Pharmaceuticals Amino acid-derived compounds as modulators of the reverse cholesterol transport
WO2007055873A2 (en) * 2005-11-04 2007-05-18 Avanir Pharmaceuticals Process for the manufacture of peptide facilitators of reverse cholesterol transport
CA2787343C (en) 2006-06-26 2016-08-02 Amgen Inc. Compositions comprising modified lcat and uses thereof
US20100324075A1 (en) * 2007-12-21 2010-12-23 University Of Cincinnati Therapeutic use of carboxyl ester lipase inhibitors
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
US20110152112A1 (en) * 2009-12-23 2011-06-23 Artery Therapeutics, Inc. Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases
US20110288017A1 (en) * 2010-03-01 2011-11-24 Leslie Frost Apo-lipoprotein propeptide
US11840707B2 (en) 2016-05-31 2023-12-12 Institut De Cardiologie De Montreal Co-culture system and method for in vitro assessment of reverse cholesterol transport
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (en) 2019-01-18 2021-09-21 Astrazeneca Ab PCSK9 INHIBITORS AND METHODS OF USING THEM
WO2023277508A1 (en) * 2021-06-28 2023-01-05 (주)메디엔진 Peptide having antidiabetic activity and use thereof
CN113929737B (en) * 2021-10-20 2024-07-23 中国科学院香港创新研究院再生医学与健康创新中心 A polypeptide and its application as CCK receptor agonist/antagonist
WO2025024564A1 (en) * 2023-07-24 2025-01-30 The Board Of Regents Of The University Of Texas System Small molecules that prevent statin-induced accumulation of hmg coa reductase

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0162414A2 (en) * 1984-05-15 1985-11-27 Research Corporation Amphipathic peptides and pharmaceutical compositions containing same
WO1999016408A2 (en) * 1997-09-29 1999-04-08 Dasseux Jean Louis Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders
WO2002038609A2 (en) * 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
WO2002083917A2 (en) * 2001-04-10 2002-10-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE437153B (en) * 1976-12-01 1985-02-11 Kabi Ab SPECIFIC CHROMOGENA ENZYM SUBSTATE FOR SERINE PROTEASES
US4448715A (en) * 1981-11-02 1984-05-15 University Of Miami Tagged pyroglu-L-Phe-L-Arg derivatives, substrates and assays for kallikrein
CA1311583C (en) * 1986-12-15 1992-12-15 Gerard Armand Marguerie De Rotrou Peptide derivatives and their application, in particular in therapy
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
WO1999003880A1 (en) * 1997-07-15 1999-01-28 Novo Nordisk A/S Nociceptin analogues
US6821774B1 (en) * 1999-06-18 2004-11-23 Cv Therapeutics, Inc. Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter ABC1
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0162414A2 (en) * 1984-05-15 1985-11-27 Research Corporation Amphipathic peptides and pharmaceutical compositions containing same
WO1999016408A2 (en) * 1997-09-29 1999-04-08 Dasseux Jean Louis Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders
WO2002038609A2 (en) * 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
WO2002083917A2 (en) * 2001-04-10 2002-10-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BANKA CL ET AL.: "Localization of an Apolipoprotein A-I Epitope Critical for Activation of Lecithin-Cholesterol Acyltransferase", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 35, 15 December 1991 (1991-12-15), pages 23886 - 23892, XP002299434 *

Also Published As

Publication number Publication date
NO20055474D0 (en) 2005-11-18
BRPI0409609A (en) 2006-04-18
US20060166891A1 (en) 2006-07-27
TW200503747A (en) 2005-02-01
EP1615954A2 (en) 2006-01-18
WO2004094471A2 (en) 2004-11-04
IS8072A (en) 2005-10-13
NO20055474L (en) 2006-01-23
AU2004233333A1 (en) 2004-11-04
JP2007534612A (en) 2007-11-29
PE20050136A1 (en) 2005-04-20
KR20050114283A (en) 2005-12-05
CL2004000858A1 (en) 2005-04-22
RU2005135139A (en) 2007-05-27
UY28282A1 (en) 2004-11-30
CA2522758A1 (en) 2004-11-04
CN1809590A (en) 2006-07-26
MXJL05000046A (en) 2005-12-22
AR044058A1 (en) 2005-08-24

Similar Documents

Publication Publication Date Title
MXJL05000046A (en) Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia.
WO2004052280A3 (en) Anti-angiogenic compounds and their use in cancer treatment
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
WO2006045096A3 (en) Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
WO2004094596A8 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2004006858A3 (en) Compounds, compositions, and methods employing same
AU2003901008A0 (en) Composition for the treatment and prevention of bacterial infections
WO2006024018A3 (en) Compositions for treating nociceptive pain
NO20070139L (en) Heterocyclic derivatives for the treatment of hyperlipidemia and related diseases
WO2005102392A3 (en) Combinations for treating hiv infection
WO2004087100A3 (en) Cladribine formulations for improved oral and transmucosal delivery
WO2006034001A3 (en) Methods of treating hiv infection
AU2003232115A1 (en) Methods and compositions for the treatment of graft failure
AP2006003557A0 (en) Antimalarial compositions and process thereof.
WO2003072053A3 (en) Compounds for treatment of copper overload
WO2006012504A3 (en) Compounds and methods for treatment of thrombosis
WO2006020430A8 (en) Novel composition and methods for the treatment of immune related disease
ZA200502464B (en) Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome.
TW200603795A (en) Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
TW200603794A (en) Small molecules for treatment of hypercholesterolemia and related diseases
ZA200408272B (en) Compositions for improving the flavor of alcoholicbeverage made from grape.
WO2004096848A8 (en) Novel composition and methods for the treatment of immune disorders
WO2005027832A3 (en) Edta containing compositions and uses thereof
WO2005110391A3 (en) Compounds for treating human papillomavirus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004233333

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 171394

Country of ref document: IL

Ref document number: 542934

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004760126

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2522758

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: JL/a/2005/000046

Country of ref document: MX

Ref document number: 1020057020078

Country of ref document: KR

Ref document number: 2006513224

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004233333

Country of ref document: AU

Date of ref document: 20040422

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004233333

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200509174

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 05117186

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2005135139

Country of ref document: RU

Ref document number: 2339/KOLNP/2005

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 1020057020078

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20048174775

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004760126

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0409609

Country of ref document: BR